Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT302
- Development stage
- Preclinical
- Lead developer
- Myeloid Therapeutics
- Administration
- Intravenous
01
Overview
**MT302** is a preclinical Mthera Pharma drug candidate for **cancer cachexia**. Mthera Pharma lists the asset as **NB-02** and describes it as developed using its proprietary **MCMT multi-component multi-target platform**. The specific active constituents, modality, molecular targets, route of administration, and mechanism of action have not been publicly disclosed.
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on MT302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT302.